AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16169705 — intervention group
Group type: COMPARATOR
Intervention: Battery change scores calculated by summing z-scores of change for each individual test
Number of subjects: 57
Study 16169705 — intervention group
Group type: COMPARATOR
Intervention: Battery RCI normative standards
Number of subjects: 57
Study 14648082 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program for ankylosing spondylitis
Number of subjects: 0
Study 14648082 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10624992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (20 mL)
Number of subjects: 50
Study 10624992 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (20 mL)
Number of subjects: 50
Study 9179174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact aerobic exercise for 12 weeks
Number of subjects: 25
Study 23087954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with a rubber cup and pumice
Number of subjects: 45
Study 23087954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with a rubber cup and nonfluoridated paste
Number of subjects: 45
Study 23087954 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with a rubber cup and fluoridated paste
Number of subjects: 45
Study 3757512 — intervention group
Group type: EXPERIMENTAL
Intervention: Microgynon 30 (150 micrograms levonorgestrel and 30 micrograms ethinyl oestradiol)
Number of subjects: 14
Study 31736123 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Ablative Fractional Resurfacing Laser Treatment (FLR)
Number of subjects: 30
Study 31736123 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated arm)
Number of subjects: 30
Study 29033355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia tramadol + SAPB (Group S)
Number of subjects: 40
Study 29033355 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia tramadol (Group T)
Number of subjects: 40
Study 29033355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27067393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac 3% gel
Number of subjects: 128
Study 27067393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (diclofenac and calcitriol)
Number of subjects: 128
Study 27067393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no topical treatment)
Number of subjects: 128
Study 27067393 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcitriol 3 μg/g ointment
Number of subjects: 128
Study 24316342 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 92
Study 24316342 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide
Number of subjects: 92
Study 22652344 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521) and AIDSVAX B/E vaccine regimen
Number of subjects: 16395
Study 22652344 — intervention group
Group type: EXPERIMENTAL
Intervention: High or increasing risk behaviour
Number of subjects: 16395
Study 22652344 — intervention group
Group type: COMPARATOR
Intervention: Vaccination
Number of subjects: 16395
Study 20633581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 0
Study 20633581 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18783504 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion sustained-release (SR) treatment
Number of subjects: 403
Study 18783504 — intervention group
Group type: COMPARATOR
Intervention: placebo pill
Number of subjects: 403
Study 15629356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexavalent DTPa-HBV-IPV/Hib vaccine
Number of subjects: 9199
Study 15629356 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV/Hib and HBV vaccines administered separately
Number of subjects: 9199
Study 14521290 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression (ASD)
Number of subjects: 34
Study 14521290 — intervention group
Group type: COMPARATOR
Intervention: Open subacromial decompression (OSD)
Number of subjects: 34
Study 9882287 — intervention group
Group type: EXPERIMENTAL
Intervention: cpts530/1030
Number of subjects: 0
Study 9882287 — intervention group
Group type: EXPERIMENTAL
Intervention: cpts248/404/1030
Number of subjects: 0
Study 9882287 — intervention group
Group type: COMPARATOR
Intervention: cpts248/404
Number of subjects: 0
Study 8742147 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious conditions
Number of subjects: 474
Study 8742147 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory infections
Number of subjects: 474
Study 8742147 — intervention group
Group type: EXPERIMENTAL
Intervention: Total infections
Number of subjects: 474
Study 8742147 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections by month
Number of subjects: 474
Study 1750315 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% clonidine
Number of subjects: 63
Study 1750315 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 63
Study 7038491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 138
Study 7038491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 31814044 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (intravenous magnesium sulfate to maintain serum magnesium level around 3 mg/dL for 3 days)
Number of subjects: 58
Study 31814044 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 58
Study 31814044 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 58
Study 31814044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 31388184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protein biomarker panel (CA125, phosphatidylcholine‐sterol acyltransferase, vitamin K‐dependent protein Z and C‐reactive protein)
Number of subjects: 49
Study 31388184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined protein biomarker panel
Number of subjects: 49
Study 29702040 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grains diet
Number of subjects: 75
Study 29702040 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 75
Study 29702040 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet (whole grains and fruits and vegetables)
Number of subjects: 75
Study 27104803 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation cognitive therapy (C-CT)
Number of subjects: 241
Study 27104803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 241
Study 27104803 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo (PBO) plus clinical management
Number of subjects: 241
Study 27104803 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute-phase cognitive therapy (CT)
Number of subjects: 241
Study 27104803 — intervention group
Group type: EXPERIMENTAL
Intervention: Deteriorating social-interpersonal functioning
Number of subjects: 241
Study 25058804 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder distention before outpatient hysteroscopy (OH)
Number of subjects: 102
Study 25058804 — intervention group
Group type: COMPARATOR
Intervention: No bladder distention (control group)
Number of subjects: 102
Study 22134624 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg minodronate once a day
Number of subjects: 380
Study 22134624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first 2 years) then minodronate (year 3)
Number of subjects: 380
Study 19496635 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 124
Study 19496635 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 124
Study 17205494 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilayer compression treatment with ULSA score of 50 or less
Number of subjects: 229
Study 17205494 — intervention group
Group type: COMPARATOR
Intervention: Multilayer compression treatment with ULSA score of greater than 50
Number of subjects: 229
Study 16008934 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 52
Study 12090459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate (low stability constant)
Number of subjects: 10
Study 12090459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (low stability constant)
Number of subjects: 10
Study 12090459 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc citrate (high stability constant)
Number of subjects: 10
Study 12090459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-acid chelated zinc (extremely high stability constant)
Number of subjects: 10
Study 11193270 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine
Number of subjects: 21
Study 11193270 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 21
Study 11193270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Epidural bupivacaine and Intravenous morphine)
Number of subjects: 21
Study 8933241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate treatment
Number of subjects: 1002
Study 8933241 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (Control)
Number of subjects: 1002
Study 1606457 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents
Number of subjects: 0
Study 1606457 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant agents
Number of subjects: 0
Study 1606457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinolytic agents
Number of subjects: 0
Study 3918145 — intervention group
Group type: COMPARATOR
Intervention: Enteral formula containing 14% of its calories as protein
Number of subjects: 20
Study 3918145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formula containing 22% protein calories
Number of subjects: 20
Study 31590926 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led care coordination during transition from inpatient to community setting with follow-up medication therapy management (MTM) by community pharmacists.
Number of subjects: 96
Study 31590926 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication therapy management (MTM) provided by community pharmacists postdischarge.
Number of subjects: 96
Study 29906916 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-respecting null model randomization methodology
Number of subjects: 0
Study 28850471 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mg morphine into inflamed tissue
Number of subjects: 88
Study 28850471 — intervention group
Group type: COMPARATOR
Intervention: 2mg morphine into non-inflamed tissue
Number of subjects: 88
Study 28850471 — intervention group
Group type: COMPARATOR
Intervention: IM morphine
Number of subjects: 88
Study 28850471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation scores
Number of subjects: 88
Study 28850471 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first analgesic intake
Number of subjects: 88
Study 28850471 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious side effects
Number of subjects: 88
Study 24685276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 1083
Study 24685276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1083
Study 22712480 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma F₂‐isoprostanes (F₂‐IsoPs)
Number of subjects: 233
Study 22712480 — intervention group
Group type: EXPERIMENTAL
Intervention: Isofurans (IsoFs)
Number of subjects: 233
Study 22712480 — intervention group
Group type: EXPERIMENTAL
Intervention: F₂‐IsoPs
Number of subjects: 233
Study 22712480 — intervention group
Group type: EXPERIMENTAL
Intervention: IsoFs
Number of subjects: 233
Study 22712480 — intervention group
Group type: EXPERIMENTAL
Intervention: WC, SBP, and sex
Number of subjects: 233
Study 20427088 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab + prompt laser
Number of subjects: 691
Study 20427088 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab + deferred laser
Number of subjects: 691
Study 20427088 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg triamcinolone + prompt laser
Number of subjects: 691
Study 20427088 — intervention group
Group type: COMPARATOR
Intervention: sham injection + prompt laser
Number of subjects: 691
Study 18227475 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump therapy (CSII)
Number of subjects: 0
Study 18227475 — intervention group
Group type: COMPARATOR
Intervention: Long-acting insulin analogs (glargine and detemir)
Number of subjects: 0
Study 15522901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity pre-conditioning exercise programme linked with exercise counselling
Number of subjects: 96
Study 15522901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise programme)
Number of subjects: 96
Study 12576840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to points of the kidney-bladder distinct meridian
Number of subjects: 30
Study 12576840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture to points not expected to treat the prostate
Number of subjects: 30
Study 12576840 — intervention group
Group type: COMPARATOR
Intervention: Observation for 3 months
Number of subjects: 30
Study 10560985 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone vaginal progesterone gel (90 mg once daily)
Number of subjects: 206
Study 10560985 — intervention group
Group type: COMPARATOR
Intervention: IM progesterone (50 mg once daily)
Number of subjects: 206
Study 8904262 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol
Number of subjects: 50
Study 8904262 — intervention group
Group type: COMPARATOR
Intervention: Inhalation anesthesia with nitrous oxide and isoflurane
Number of subjects: 50
Study 1870360 — intervention group
Group type: EXPERIMENTAL
Intervention: clebopride + simethicone (Flatoril)
Number of subjects: 0
Study 31689480 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (Fufang Chuanxiong Capsule and Xinyue Capsule)
Number of subjects: 426
Study 31689480 — intervention group
Group type: COMPARATOR
Intervention: Western medicine standard therapy
Number of subjects: 426
Study 30419066 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a musically-enriched environment (listening to music at home, during play, or attending concerts)
Number of subjects: 176
Study 30419066 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a musically-enriched environment
Number of subjects: 176
Study 27761657 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (3‐min intervals at 40 and 80 % VO2max for five repetitions, n = 20)
Number of subjects: 60
Study 27761657 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT
Number of subjects: 60
Study 27761657 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (sustained 60 % VO2max, n = 20)
Number of subjects: 60
Study 27761657 — intervention group
Group type: COMPARATOR
Intervention: CTL (control group, n = 20)
Number of subjects: 60
Study 24565955 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrasentan (bone targeted endothelin-A receptor antagonist)
Number of subjects: 778
Study 24565955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 778
Study 22316089 — intervention group
Group type: EXPERIMENTAL
Intervention: LGS-On (low glucose suspend feature turned on)
Number of subjects: 50
Study 22316089 — intervention group
Group type: COMPARATOR
Intervention: LGS-Off (continued insulin delivery regardless of SG value)
Number of subjects: 50
Study 22316089 — intervention group
Group type: EXPERIMENTAL
Intervention: LGS-On
Number of subjects: 50
Study 22316089 — intervention group
Group type: COMPARATOR
Intervention: LGS-Off
Number of subjects: 50
Study 20658925 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ice in a room temperature wet towel
Number of subjects: 25
Study 20658925 — intervention group
Group type: COMPARATOR
Intervention: Liquid Ice
Number of subjects: 25
Study 18619520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric chamber at 4000m altitude
Number of subjects: 10
Study 15762941 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel items (new materials not presented earlier in Phase 1)
Number of subjects: 0
Study 15762941 — intervention group
Group type: COMPARATOR
Intervention: Familiar items (materials encoded earlier in Phase 1)
Number of subjects: 0
Study 12446370 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.1%
Number of subjects: 180
Study 12446370 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1%
Number of subjects: 180
Study 12446370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 180
Study 10521964 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg every 3 hours
Number of subjects: 20
Study 10521964 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg every 6 hours
Number of subjects: 20
Study 10521964 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg every 12 hours
Number of subjects: 20
Study 8541198 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular Maxon
Number of subjects: 114
Study 8541198 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted nylon
Number of subjects: 114
Study 8541198 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nylon
Number of subjects: 114
Study 8541198 — intervention group
Group type: EXPERIMENTAL
Intervention: Clips
Number of subjects: 114
Study 8541198 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 1685793 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone (0.1 mg tid)
Number of subjects: 54
Study 1685793 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone (0.2 mg tid)
Number of subjects: 54
Study 1685793 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone (0.3 mg tid)
Number of subjects: 54
Study 1685793 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone (0.4 mg tid)
Number of subjects: 54
Study 1685793 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg tid)
Number of subjects: 54
Study 1685793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 6814226 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 63
Study 6814226 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of Verapamil
Number of subjects: 63
Study 30911917 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 47
Study 30911917 — intervention group
Group type: COMPARATOR
Intervention: Non-CHM control group
Number of subjects: 47
Study 29847468 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 to 2 mg/kg)
Number of subjects: 50
Study 29847468 — intervention group
Group type: COMPARATOR
Intervention: Methohexital (1 to 2 mg/kg)
Number of subjects: 50
Study 26781292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive mobile App (Strengthen your ankle)
Number of subjects: 220
Study 26781292 — intervention group
Group type: COMPARATOR
Intervention: Regular written exercise materials (Booklet)
Number of subjects: 220
Study 24745863 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger point acupuncture (TrP)
Number of subjects: 18
Study 24745863 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SH)
Number of subjects: 18
Study 21664707 — intervention group
Group type: EXPERIMENTAL
Intervention: RVEF 30-39%
Number of subjects: 822
Study 21664707 — intervention group
Group type: EXPERIMENTAL
Intervention: RVEF 20-29%
Number of subjects: 822
Study 21664707 — intervention group
Group type: EXPERIMENTAL
Intervention: RVEF <20%
Number of subjects: 822
Study 21664707 — intervention group
Group type: COMPARATOR
Intervention: RVEF ≥ 40%
Number of subjects: 822
Study 19396947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day)
Number of subjects: 30
Study 19396947 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50 mg/day)
Number of subjects: 30
Study 19396947 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 30
Study 16406475 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief health counseling, self-help materials on smoking cessation during pregnancy and early postpartum, and a partner booklet.
Number of subjects: 118
Study 16406475 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group).
Number of subjects: 118
Study 14700340 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% EDTA gel applied for 15 seconds
Number of subjects: 0
Study 14700340 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% EDTA gel applied for 1 minute
Number of subjects: 0
Study 14700340 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% EDTA gel applied for 3 minutes
Number of subjects: 0
Study 10965426 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexpanthenol
Number of subjects: 0
Study 10965426 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 8854787 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU + MMC +/‐ ADR (group I)
Number of subjects: 97
Study 8854787 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP + MMC +/‐ 5‐FU (group II)
Number of subjects: 97
Study 8854787 — intervention group
Group type: EXPERIMENTAL
Intervention: IAIC with radiotherapy
Number of subjects: 97
Study 8854787 — intervention group
Group type: EXPERIMENTAL
Intervention: IAIC without radiotherapy
Number of subjects: 97
Study 8854787 — intervention group
Group type: EXPERIMENTAL
Intervention: All cases
Number of subjects: 97
Study 8854787 — intervention group
Group type: EXPERIMENTAL
Intervention: CR cases
Number of subjects: 97
Study 8854787 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal iliac arteries placement
Number of subjects: 97
Study 1337833 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide in lomustine cycles
Number of subjects: 79
Study 1337833 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate in lomustine cycles
Number of subjects: 79
Study 6392216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Number of subjects: 13
Study 6392216 — intervention group
Group type: EXPERIMENTAL
Intervention: Polished rice
Number of subjects: 13
Study 6392216 — intervention group
Group type: EXPERIMENTAL
Intervention: White beans
Number of subjects: 13